IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?

Andy Gould, The Motley Fool
Fri, July 10, 2026 at 4:31 PM GMT+5:30
4 min read

• ^GSPC
  +0.81%

Investors seeking exposure to healthcare innovation often have to choose between the stability of established pharmaceutical giants and the higher-growth, higher-risk profile of clinical-stage biotech firms. This comparison looks at the two popular funds — the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the iShares Biotechnology ETF (NASDAQ:IBB)– to see how their differing concentration, volatility, and income potential might fit different long-term strategies

Snapshot (cost & size)

Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield

IHE is the cheaper option, with an expense ratio of 0.38% versus 0.44% for IBB. IHE also has a higher dividend, with a yield advantage of 1.26 percentage points over IBB

Performance & risk comparison

What’s inside

Launched in 2006, IHE focuses on the traditional drug manufacturing sector and maintains a relatively concentrated portfolio of just 56 holdings. Its largest positions include Johnson & Johnson (NYSE:JNJ) at 22.4%, Eli Lilly (NYSE:LLY) at 22.3%, and Merck (NYSE:MRK) at 4.6%

IBB casts a much wider net, holding 248 companies for broader exposure across the biotech landscape. Its largest positions include Vertex Pharmaceuticals (NASDAQ:VRTX) at 8.1%, Amgen (NASDAQ:AMGN) at 7.8%, and Gilead Sciences (NASDAQ:GILD) at 6.8%. IBB was launched in 2001

For more guidance on ETF investing, check out the full guide at this link

What this means for investors

These two funds represent different philosophies on healthcare investing. IHE’s holdings are dominated by companies that already sell blockbuster drugs and generate steady, predictable cash flow. That’s why it can afford to pay a meaningfully higher dividend and why its five-year returns have come with a smoother ride. Big pharma companies tend to be defensive holdings — people need medicine during good times and bad — which helps explain IHE’s lower volatility

IBB, on the other hand, is built for investors chasing the next breakthrough. Clinical-stage biotech firms often plow every available dollar back into research and drug trials rather than paying dividends, and their stock prices can swing wildly on a single clinical trial result or FDA decision. That’s the trade-off: IBB’s 248 holdings offer diversification across many potential winners, but any individual biotech blowup or breakthrough can still have an impact